Bolt Biotherapeutics Announces Acquisition of Prana Therapies and $120 Million Concurrent Private Placement to Advance PRA-216 in Multiple High-Value Inflammatory IndicationsGlobeNewsWire · 2 days ago
Bolt Biotherapeutics (NASDAQ:BOLT) Share Price Breaks Above Two Hundred Day Moving Average – Time to Sell?Defense World · 4 days ago
Bolt Biotherapeutics (NASDAQ:BOLT) Stock Price Crosses Below 200-Day Moving Average – Should You Sell?Defense World · Oct 7, 2026
Bolt Biotherapeutics (NASDAQ:BOLT) VP Sarah Nemec Sells 4,077 SharesDefense World · Sep 22, 2026
Bolt Biotherapeutics (NASDAQ:BOLT) COO Grant Yonehiro Sells 4,909 Shares of StockDefense World · Sep 22, 2026
Bolt Biotherapeutics, Inc. (BOLT) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research · Aug 11, 2026Bolt Biotherapeutics, Inc. is a biotechnology company currently conducting clinical trials, focused on developing innovative immuno-oncology therapies. Its mission is to create agents that equip the body's immune system to identify and eliminate cancerous cells. A key therapeutic in its pipeline is BDC-1001, an investigational treatment targeting the human epidermal growth factor receptor 2 (HER2).
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 11, 2026 | -$3.39 | -$4.57 | Miss |
| May 12, 2026 | -$2.85 | -$4.31 | Miss |
| Mar 12, 2026 | -$4.30 | -$3.84 | Beat |
| Nov 12, 2025 | -$5.07 | -$3.72 | Beat |
| Aug 14, 2025 | -$6.40 | -$4.46 | Beat |
| May 12, 2025 | -$6.80 | -$5.80 | Beat |